LSX2026: On promise and patience, with Hans Schambye

At LSX World Congress 2026 in Lisbon, Portugal, web editor Nicole Raleigh spoke with Hans Schambye, CEO of BOOST Pharma, a clinical stage biopharmaceutical company developing novel, first in class stem cell therapies for rare, debilitating paediatric skeletal diseases.

From BOOST’s allogeneic mesenchymal stem cell therapy for osteogenesis imperfecta to the company’s investment experience, Schambye discusses the conference as a whole, including key insights and forward-looking trends for biotechs.

Find this and other conversations from LSX World Congress on our Spotlight On page for BIO-Europe.